

Company Press Release

CardioMEMS, Inc. Announces 510(k) Clearance and U.S. Launch of the EndoSure™ Wireless AAA Pressure Measurement System

Device is intended for measuring intrasac pressure during endovascular abdominal aortic aneurysm (AAA) repair and may be used as an adjunctive tool in the detection of intraoperative endoleaks.

Atlanta – November 1, 2005. CardioMEMS, Inc. announced today U.S. Food and Drug Administration (FDA) clearance and U.S. market launch of the EndoSure™ Wireless AAA Pressure Measurement System. FDA clearance was based upon completion of a multi-center, international clinical study in which over 100 patients in Brazil, Argentina, Canada and at nine hospitals in the United States successfully received an *EndoSure* sensor at the same time they had a stent-graft inserted to repair their aortic aneurysm. Implantation of the *EndoSure* Wireless AAA Pressure Sensor did not lead to any adverse events in the clinical trial.

The revolutionary *EndoSure* Sensor is the first wireless, un-powered, permanently implantable pressure sensor for human use to be commercially available in the United States. The system is based on the latest innovations in both microelectromechanical systems (MEMS) and wireless technologies, and comprises the *EndoSure* Sensor, a unique delivery catheter, the external interrogation device and proprietary software. The *EndoSure* Wireless AAA Pressure Sensor is implanted during the endovascular aortic repair (EVAR) procedure and is compatible with all commercially available stent-grafts. Accurate pressure measurements within the aneurysm sac can be taken simply and efficiently. To take a measurement, the physician simply places the antenna on the patient's abdomen and activates the Sensor using low power radio-frequency energy. A real-time, high-resolution pressure waveform is quickly displayed on a 15" flat-panel touch screen monitor.

"We believe the *EndoSure* AAA Pressure Measurement System represents breakthrough technology that will provide a significant benefit both to the patient as well as to the physician performing endovascular aneurysm repair" said David Stern, President and CEO of CardioMEMS, Inc. "The results of our clinical trial demonstrate that we have developed a product that is safe and easy to use."

Dr. Takao Ohki, Professor and Chief of Vascular Surgery at Montefiore Medical Center, Co-Principal investigator of the CardioMEMS, Inc. APEX clinical trial (Acute Pressure measurement to confirm aneurysm EXclusion) and the first physician in the world to implant the sensor in a patient commented "The implantation of the *EndoSure* is straightforward and safe. I believe that over time this important new technology may demonstrate its value by helping physicians

confirm that aneurysms have been effectively treated with EVAR procedures and also identify problems that may arise” Preliminary results of the APEX trial were presented in June 2005 by Dr. Ohki at the Society of Vascular Surgery annual meeting in Chicago.

The company will begin taking orders and shipping the *EndoSure* Sensor to customers immediately according to Kevin Corcoran, Vice-President of Sales and Marketing. “We have assembled a first class sales and engineering team that will provide the highest level of customer support to meet the ever increasing demand for pressure measurements during EVAR procedures.”

About CardioMEMS, Inc.

CardioMEMS, Inc. is a medical device company focused on the application of Microelectromechanical systems (MEMS) technology to create innovative devices for the diagnosis and management of chronic diseases. CardioMEMS, Inc. has already developed implantable wireless sensors targeted for the Aortic Aneurysm and Congestive Heart Failure (CHF) markets and continues to explore additional applications of the technology. There are approximately 200,000 new cases of Aortic Aneurysms diagnosed each year in the U.S. and it is the 3rd leading cause of sudden death. CHF affects approximately 5 million people in the U.S. and is the leading cause of hospitalizations with almost a million admissions last year.

CardioMEMS, Inc. is located in Atlanta, GA and is privately held. More information about CardioMEMS, Inc. can be found at www.cardiomems.com

Statements made in this press release that look forward in time or that express beliefs, expectations or hopes regarding future occurrences or anticipated outcomes are forward-looking statements. A number of risks and uncertainties such as risks associated with product development and commercialization efforts, results of clinical trials, ultimate clinical outcome and benefit of the Company’s products, market and physician acceptance of the products, intellectual property protection, and competitive offerings could cause actual events to adversely differ from the expectations indicated in these forward looking statements.

Contact:
Sandeep Yadav, CFO, 404-920-6700

CardioMEMS and *EndoSure* are trademarks of CardioMEMS, Inc.